DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Recommendation of “Moderate Buy” from Analysts

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $12.3333.

DMAC has been the topic of several analyst reports. Wall Street Zen downgraded DiaMedica Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Monday, April 20th.

DiaMedica Therapeutics Price Performance

DMAC stock opened at $6.06 on Monday. DiaMedica Therapeutics has a twelve month low of $3.47 and a twelve month high of $10.42. The stock has a market cap of $326.51 million, a P/E ratio of -8.54 and a beta of 0.99. The business’s 50-day moving average price is $6.68 and its 200-day moving average price is $7.54.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). On average, equities research analysts expect that DiaMedica Therapeutics will post -0.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DMAC. Cooperman Leon G increased its position in DiaMedica Therapeutics by 98.2% during the 3rd quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock valued at $22,463,000 after buying an additional 1,619,761 shares in the last quarter. Millennium Management LLC acquired a new stake in DiaMedica Therapeutics during the third quarter worth about $8,157,000. Geode Capital Management LLC grew its stake in shares of DiaMedica Therapeutics by 99.6% during the 2nd quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock worth $2,458,000 after purchasing an additional 314,407 shares during the period. Paragon Associates & Paragon Associates II Joint Venture grew its position in DiaMedica Therapeutics by 34.6% during the third quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock valued at $6,011,000 after buying an additional 225,000 shares during the period. Finally, Royal Bank of Canada grew its position in DiaMedica Therapeutics by 46,879.1% during the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after buying an additional 154,701 shares during the period. 10.12% of the stock is owned by institutional investors and hedge funds.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.